A Phase 4 interventional study of adenosylcobalamin in Premature Ovarian Insufficiency (POI) and Diminished Ovarian Reserve (DOR), sponsored by Tongji Hospital. Not yet recruiting. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:
Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?
Participants will:
Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests
182 studies on the registry are indexed under Primary Ovarian Insufficiency; 49 are open to participants now.
This study's planned enrollment of 48 is close to the median of 48 across 114 interventional studies indexed under Primary Ovarian Insufficiency.
Browse Primary Ovarian Insufficiency studies →Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(2) Diminished ovarian reserve (DOR): Age \< 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (\< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (\< 6) and/or an elevated basal FSH level (> 10 U/L).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: adenosylcobalamin
Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks.
anti-müllerianhormone
The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.
Time frame: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
sex hormones
The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.
Time frame: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
antral follicles
The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.
Time frame: Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobamamide
Primary Ovarian Insufficiency →